UNIFYING HERBAL MEDICINE AND MODERN PHARMACEUTICAL DELIVERY VIA CURCUMIN TRANSDERMAL PATCHES
DOI:
https://doi.org/10.64261/40brt540Keywords:
Controlled Release, Curcumin, Nanotechnology, Phytomedicine, Polymeric Patch, Skin Penetration, Transdermal Drug DeliveryAbstract
Traditional herbal therapy has long praised curcumin, the main bioactive component of Curcuma longa, for its anti-inflammatory, antioxidant, and wound-healing qualities. However, due to its weak water solubility, rapid metabolism, and limited systemic availability when administered orally, its therapeutic potential has remained limited. Transdermal drug delivery systems (TDDS), which provide patient-friendly dosing, enhanced bioavailability, and controlled penetration, have emerged as a revolutionary approach to overcoming these limitations. Transdermal curcumin patches are an inventive fusion of traditional phytotherapy and contemporary pharmaceutical technologies. To efficiently transport curcumin across the stratum corneum, these patches are designed with polymeric matrices, permeation enhancers, and adhesive coatings. The patches enhance therapeutic efficacy while minimizing gastrointestinal distress by bypassing hepatic first-pass metabolism and maintaining consistent plasma concentrations. Curcumin-loaded nanoparticles, nano-emulsions, and microneedle-assisted systems are recent developments in nanotechnology that further enhance skin penetration and stability, broadening their potential clinical uses in dermatological disorders, chronic inflammation, pain management, and systemic conditions that need long-term therapy. Furthermore, the use of herbal-compatible and biodegradable polymers is in line with the increasing need for sustainable and biocompatible medication delivery systems across the world. Early clinical evaluations show better patient compliance and treatment outcomes, while preclinical studies show encouraging findings in terms of safety, permeation efficiency, and pharmacodynamic activity. Despite these benefits, there are still issues with long-term clinical validation, regulatory procedures, stability optimization, and large-scale production. All things considered, curcumin transdermal patches represent a significant advancement in fusing conventional herbal knowledge with cutting-edge medication delivery technology. They are positioned as a potential frontier in herbal-based pharmaceutical innovation because of their capacity to transform a centuries-old natural medicine into a precisely regulated medicinal system.
References
1. Ekor M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol. 2014;4:177.
2. WHO. Traditional Medicine Strategy 2014–2023. World Health Organization; 2013.
3. Patwardhan B, Mashelkar RA. Traditional medicine-inspired approaches to drug discovery. Drug Discov Today. 2009;14(15–16):804–811.
4. Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin. Int J Biochem Cell Biol. 2009;41(1):40–59.
5. Hewlings SJ, Kalman DS. Curcumin: a review of its effects on human health. Foods. 2017;6(10):92.
6. Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin. AAPS J. 2013;15(1):195–218.
7. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin. Mol Pharm. 2007;4(6):807–818.
8. Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26(11):1261–1268.
9. Brown MB, et al. Dermal and transdermal drug delivery systems. Drug Deliv. 2006;13(3):175–187.
10. Barry BW. Breaching the skin’s barrier to drugs. Nat Biotechnol. 2004;22(2):165–167.
11. Ita K. Transdermal delivery of drugs with microneedles. J Pharm Pharmacol. 2015;67(7):821–827.
12. Naik A, Kalia YN, Guy RH. Transdermal drug delivery. Adv Drug Deliv Rev. 2000;56(5):619–628.
13. Williams AC, Barry BW. Penetration enhancers. Adv Drug Deliv Rev. 2012;64:128–137.
14. Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as a therapeutic agent. Biochem Pharmacol. 2008;75(4):787–809.
15. Singh SP, et al. Transdermal drug delivery systems: a review. Int J Pharm Sci Res. 2011;2(7):1683–1693.
16. EMA. Guideline on quality of herbal medicinal products. European Medicines Agency; 2011.
17. Aggarwal BB, et al. Curcumin: the Indian solid gold. Adv Exp Med Biol. 2007;595:1–75.
18. Vogel H, Pelletier J. Curcumin isolation studies. J Pharm. 1815;1:289–300.
19. Gupta SC, et al. Therapeutic roles of curcumin. AAPS J. 2013;15(1):195–218.
20. Anand P, et al. Bioavailability of curcumin. Mol Pharm. 2007;4(6):807–818.
21. Brown MB, et al. Dermal and transdermal drug delivery systems. Drug Deliv. 2006;13(3):175–187.
22. Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26(11):1261–1268.
23. Barry BW. Novel mechanisms and devices to enable transdermal drug delivery. Eur J Pharm Sci. 2001;14(2):101–114.
24. Brown MB, et al. Dermal and transdermal drug delivery systems. Drug Deliv. 2006;13(3):175–187.
25. Barry BW. Breaching the skin’s barrier to drugs. Nat Biotechnol. 2004;22(2):165–167.
26. Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26(11):1261–1268.
27. Guy RH, Hadgraft J. Transdermal drug delivery. Drug Deliv. 2003;10(2):75–82.
28. Williams AC, Barry BW. Penetration enhancers. Adv Drug Deliv Rev. 2012;64:128–137.
29. Ita K. Transdermal delivery of drugs with microneedles. J Pharm Pharmacol. 2015;67(7):821–827.
30. Touitou E, et al. Ethosomes—novel vesicular carriers. J Control Release. 2000;65(3):403–418.
31. Subash R, Revathi S, Akilandeswari S. Recent Advances in Transdermal Drug Delivery System and its Utilization in Herbal Medicines — a review of types, advancements, and effectiveness of herbal TDDS. Pharmacognosy Research, 2025;17(2):380–384.
32. Vichare SS et al. Transdermal Delivery of Herbal Extracts: Techniques, Polymers, and Permeation Enhancers — analysis of formulation methods and recent developments. International Journal of Innovative Science and Research Technology, 2025.
33. Hardainiyan S et al. A Review on Recent Innovations in Transdermal Drug Delivery for Herbal Therapy — overview of herbal TDDS and patch formulation. Journal of Biomedical and Pharmaceutical Research, 2014.
34. Patil V & Gosavi SB. Comprehensive Review of Transdermal Drug Delivery Systems: Mechanisms, Materials, and Modern Innovations — discussion of emerging nanocarrier technologies relevant to herbal actives. Asian Journal of Pharmaceutical Research and Development, 2025.
35. Barry BW. Breaching the skin’s barrier to drugs. Nat Biotechnol. 2004;22(2):165–167.
36. Elias PM. Stratum corneum architecture, metabolic activity and interactivity with subjacent cell layers. Exp Dermatol. 1996;5(4):191–201.
37. Brown MB, et al. Dermal and transdermal drug delivery systems: current and future prospects. Drug Deliv. 2006;13(3):175–187.
38. Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26(11):1261–1268.
39. Mitragotri S, et al. Overcoming the skin barrier for transdermal drug delivery. Nat Rev Drug Discov. 2014;13(9):655–672.
40. Elias PM. Epidermal lipids, barrier function, and desquamation. J Invest Dermatol. 1983;80(S1):44s–49s.
41. Bouwstra JA, Ponec M. The skin barrier in healthy and diseased state. Biochim Biophys Acta. 2006;1758(12):2080–2095.
42. Brown MB, et al. Dermal and transdermal drug delivery systems. Drug Deliv. 2006;13(3):175–187.
43. Williams AC, Barry BW. Penetration enhancers. Adv Drug Deliv Rev. 2012;64:128–137.
44. Lademann J, et al. Hair follicles—an efficient storage and penetration pathway. Skin Pharmacol Physiol. 2005;18(3):123–128.
45. Elias PM. Stratum corneum architecture, metabolic activity and interactivity. Exp Dermatol. 1996;5(4):191–201.
46. Bouwstra JA, Honeywell-Nguyen PL. Skin structure and mode of action of penetration enhancers. Adv Drug Deliv Rev. 2002;54(S1):S41–S55.
47. Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26(11):1261–1268.
48. Barry BW. Breaching the skin’s barrier to drugs. Nat Biotechnol. 2004;22(2):165–167.
49. Hadgraft J, Lane ME. Skin permeation: the years of enlightenment. Int J Pharm. 2005;305(1–2):2–12.
50. Anand P, et al. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007;4(6):807–818.
51. Hewlings SJ, Kalman DS. Curcumin: a review of its effects on human health. Foods. 2017;6(10):92.
52. Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26(11):1261–1268.
53. Brown MB, et al. Dermal and transdermal drug delivery systems. Drug Deliv. 2006;13(3):175–187.
54. Karri VVSR, et al. Transdermal delivery of curcumin. Eur J Pharm Sci. 2015;78:68–77.
55. Anand P, et al. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007;4(6):807–818.
56. Ireson CR, et al. Metabolism of curcumin in human and rat intestine. Cancer Epidemiol Biomarkers Prev. 2001;10(2):103–111.
57. Wang YJ, et al. Stability of curcumin in buffer solutions and characterization of its degradation products. J Pharm Biomed Anal. 1997;15(12):1867–1876.
58. Lao CD, et al. Dose escalation of curcuminoids in humans. BMC Complement Altern Med. 2006;6:10.
59. Hewlings SJ, Kalman DS. Curcumin: a review of its effects on human health. Foods. 2017;6(10):92.
60. Hadgraft J, Lane ME. Skin permeation: the years of enlightenment. Int J Pharm. 2005;305(1–2):2–12.
61. Karri VVSR, et al. Transdermal delivery of curcumin. Eur J Pharm Sci. 2015;78:68–77.
62. Puglia C, et al. Curcumin-loaded lipid nanoparticles. Drug Deliv. 2014;21(4):231–240.
63. Shakeel F, et al. Nanoemulsions as transdermal drug delivery systems. Curr Drug Deliv. 2012;9(4):337–351.
64. Semalty A, et al. Phytosome technology for herbal drug delivery. Fitoterapia. 2010;81(5):306–314.
65. Prausnitz MR. Microneedles for transdermal drug delivery. Adv Drug Deliv Rev. 2004;56(5):581–587.
66. Touitou E, et al. Ethosomes—novel vesicular carriers. J Control Release. 2000;65(3):403–418.
67. Cevc G, Blume G. New, highly efficient formulation of diclofenac. Biochim Biophys Acta. 2001;1514(2):191–205.
68. Uchegbu IF, Vyas SP. Non-ionic surfactant based vesicles (niosomes). Int J Pharm. 1998;172(1–2):33–70.
69. Gupta H, et al. Nanogels as a carrier for topical drug delivery. Drug Discov Today. 2016;21(2):360–372.
70. Kalia YN, et al. Iontophoretic drug delivery. Adv Drug Deliv Rev. 2004;56(5):619–658.
71. Mitragotri S. Healing sound: ultrasound-assisted drug delivery. Nat Rev Drug Discov. 2005;4(3):255–260.
72. Anand P, et al. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007;4(6):807–818.
73. Yallapu MM, et al. Curcumin: a review of its therapeutic applications. Drug Discov Today. 2012;17(1–2):71–80.
74. Karri VVSR, et al. Transdermal delivery of curcumin. Eur J Pharm Sci. 2015;78:68–77.
75. Wang YJ, et al. Stability of curcumin in buffer solutions. J Pharm Biomed Anal. 1997;15(12):1867–1876.
76. Tonnesen HH, Karlsen J. Studies on curcumin and curcuminoids. Z Lebensm Unters Forsch. 1985;180:132–134.
77. Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26(11):1261–1268.
78. Anand P, et al. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007;4(6):807–818.
79. Yallapu MM, et al. Curcumin: therapeutic applications and delivery systems. Drug Discov Today. 2012;17(1–2):71–80.
80. Guy RH, Hadgraft J. Transdermal Drug Delivery. 2nd ed. New York: Marcel Dekker; 2003.
81. Brown MB, et al. Dermal and transdermal drug delivery systems. Drug Deliv. 2006;13(3):175–187.
82. Rao PR, Diwan PV. Formulation and evaluation of polymeric films. Drug Dev Ind Pharm. 1997;23(3):327–333.
83. Williams AC, Barry BW. Penetration enhancers. Adv Drug Deliv Rev. 2012;64:128–137.
84. Karri VVSR, et al. Transdermal delivery of curcumin. Eur J Pharm Sci. 2015;78:68–77.
85. Benedek I, et al. Pressure-sensitive adhesives for transdermal systems. Drug Dev Ind Pharm. 1999;25(3):323–331.
86. Hadgraft J. Skin, the final frontier. Int J Pharm. 2001;224(1–2):1–18.
87. Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26(11):1261–1268.
88. Yallapu MM, et al. Curcumin delivery using polymeric nanoparticles. Drug Discov Today. 2012;17(1–2):71–80.
89. Puglia C, et al. Curcumin-loaded lipid nanoparticles. Drug Deliv. 2014;21(4):231–240.
90. Elsayed MMA, et al. Deformable liposomes and transdermal delivery. Int J Pharm. 2007;332(1–2):1–16.
91. Touitou E, et al. Ethosomes—novel vesicular carriers. J Control Release. 2000;65(3):403–418.
92. Cevc G, Blume G. Transfersomes for transdermal drug delivery. Biochim Biophys Acta. 2001;1514(2):191–205.
93. Gupta H, et al. Nanogels as carriers for topical drug delivery. Drug Discov Today. 2016;21(2):360–372.
94. Prausnitz MR. Microneedles for transdermal drug delivery. Adv Drug Deliv Rev. 2004;56(5):581–587.
95. Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26(11):1261–1268.
96. Brown MB, et al. Dermal and transdermal drug delivery systems. Drug Deliv. 2006;13(3):175–187.
97. Guy RH. Current status and future prospects of transdermal drug delivery. Pharm Res. 1996;13(12):1765–1769.
98. Williams AC, Barry BW. Penetration enhancers. Adv Drug Deliv Rev. 2012;64:128–137.
99. Hadgraft J, Lane ME. Skin permeation: fundamentals and application. Adv Drug Deliv Rev. 2016;97:3–13.
100. Anand P, et al. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007;4(6):807–818.
101. Shoba G, et al. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998;64(4):353–356.
102. Guy RH. Transdermal drug delivery. Pharm Res. 1996;13(12):1765–1769.
103. Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26(11):1261–1268.
104. Hadgraft J, Lane ME. Skin permeation: fundamentals and application. Adv Drug Deliv Rev. 2016;97:3–13.
105. Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin. Int J Biochem Cell Biol. 2009;41(1):40–59.
106. Gupta SC, et al. Multitargeting by curcumin as revealed by molecular interaction studies. Nat Prod Rep. 2011;28(12):1937–1955.
107. Yallapu MM, et al. Therapeutic applications of curcumin nanoformulations. AAPS J. 2015;17(6):1341–1356.
108. Brown MB, et al. Dermal and transdermal drug delivery systems. Drug Deliv. 2006;13(3):175–187.
109. Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin. Int J Biochem Cell Biol. 2009;41(1):40–59.
110. Hewlings SJ, Kalman DS. Curcumin: a review of its effects on human health. Foods. 2017;6(10):92.
111. Henrotin Y, et al. Curcumin for the management of osteoarthritis. Alternative Ther Health Med. 2014;20(Suppl 2):S3–S10.
112. Vaughn AR, et al. Natural oils for skin barrier repair. Int J Mol Sci. 2018;19(1):70.
113. Sidhu GS, et al. Curcumin enhances wound healing. Wound Repair Regen. 1998;6(2):167–177.
114. Gupta SC, et al. Multitargeting by curcumin as revealed by molecular interaction studies. Nat Prod Rep. 2011;28(12):1937–1955.
115. Tomeh MA, et al. Curcumin and cancer. Nutrients. 2019;11(4):880.
116. Mythri RB, Bharath MMS. Curcumin: a potential neuroprotective agent. Int J Pharm Sci Rev Res. 2012;14(2):30–36.
117. Panahi Y, et al. Curcumin and metabolic syndrome. Phytother Res. 2017;31(12):1827–1846.
118. Hadgraft J, Lane ME. Advanced transdermal drug delivery systems. Eur J Pharm Sci. 2016;92:2–17.
119. Karri VVSR, et al. Transdermal delivery of curcumin. Eur J Pharm Sci. 2015;78:68–77.
120. Puglia C, et al. Lipid nanoparticles for dermal delivery of curcumin. Drug Deliv. 2014;21(4):231–240.
121. Touitou E, et al. Ethosomes—novel vesicular carriers. J Control Release. 2000;65(3):403–418.
122. Elsayed MM, et al. Transfersomes as a transdermal delivery system. Int J Pharm. 2007;332(1–2):1–16.
123. Prausnitz MR. Microneedles for transdermal drug delivery. Adv Drug Deliv Rev. 2004;56(5):581–587.
124. Gupta H, et al. Nanoemulgel-based drug delivery systems. Drug Discov Today. 2016;21(2):360–372.
125. Qiu Y, Park K. Environment-sensitive hydrogels for drug delivery. Adv Drug Deliv Rev. 2012;64:49–60.
126. Dhawan S, et al. Biopolymer-based transdermal systems. J Control Release. 2019;299:119–134.
127. Genina N, et al. 3D printing of drug delivery systems. Pharmaceutics. 2020;12(3):298.
128. Yallapu MM, et al. Therapeutic applications of curcumin nanoformulations. AAPS J. 2015;17(6):1341–1356.
129. Hadgraft J, Lane ME. Skin permeation: fundamentals and application. Adv Drug Deliv Rev. 2016;97:3–13.
130. Anand P, et al. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007;4(6):807–818.
131. Wang YJ, et al. Stability of curcumin in buffer solutions. J Pharm Biomed Anal. 1997;15(12):1867–1876.
132. Williams AC, Barry BW. Penetration enhancers. Adv Drug Deliv Rev. 2012;64:128–137.
133. Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26(11):1261–1268.
134. Hewlings SJ, Kalman DS. Curcumin: a review of its effects on human health. Foods. 2017;6(10):92.
135. Qiu Y, Park K. Environment-sensitive hydrogels for drug delivery. Adv Drug Deliv Rev. 2012;64:49–60.
136. Karri VVSR, et al. Transdermal delivery of curcumin. Eur J Pharm Sci. 2015;78:68–77.
137. Puglia C, et al. Hybrid nanocarriers for dermal delivery. Drug Deliv. 2014;21(4):231–240.
138. Genina N, et al. 3D printing of personalized drug delivery systems. Pharmaceutics. 2020;12(3):298.
139. Hewlings SJ, Kalman DS. Curcumin: a review of its effects on human health. Foods. 2017;6(10):92.
140. Dhawan S, et al. Biocompatible polymers in transdermal drug delivery. J Control Release. 2019;299:119–134.
141. Yallapu MM, et al. Synergistic therapeutic applications of curcumin nanoformulations. AAPS J. 2015;17(6):1341–1356.
142. Brown MB, et al. Regulatory challenges in transdermal drug delivery. Drug Deliv. 2006;13(3):175–187.
143. Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin. Int J Biochem Cell Biol. 2009;41(1):40–59.
Downloads
Published
Issue
Section
Categories
License
Copyright (c) 2026 Pan-African Journal of Health and Psychological Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
All articles published in the Pan-African Journal of Health and Psychological Sciences (PAJHPS) are open access and distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0).
Under this license:
-
Authors retain copyright and grant the journal the right of first publication.
-
The work may be shared, copied, redistributed, and adapted for any purpose, even commercially.
-
Appropriate credit must be given to the original author(s) and the journal, along with a link to the license.
-
Users must indicate if changes were made.
-
There are no restrictions on reuse, provided the original work is properly cited.
Citation:
Authors and users must cite the original work in the following manner:
Author(s). (Year). Title of the article. Pan-African Journal of Health and Psychological Sciences, Volume(Issue), page range. https://doi.org/xx.xxxx/pajhps.vXnY.xxx
Copyright Statement:
Authors grant PAJHPS a non-exclusive license to publish the work and identify itself as the original publisher. Authors may enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version (e.g., post it to a repository or publish it in a book), with acknowledgment of its initial publication in this journal.
